ARMA BIO, INC.
Development of small molecule therapeutics targeting AR-V7 for prostate cancer
Development of small molecule therapeutics targeting AR-V7 for prostate cancer is a funding opportunity from ARMA BIO, INC., up to 888779, closing April 30, 2027.
Apr 30, 2027
(273d left)Overview
Abstract Prostate cancer is the second most commonly diagnosed cancer in men in the U.S. About 250,00 cases and 34,000 deaths from prostate cancer occur each year, making it the leading cause of cancer-related deaths in U.S. men. Incidence is so high that approximately one in every eight men will be diagnosed with the…